Perrigo Earnings Call: Cost Cuts, Headwinds, and Hopes
Perrigo Company ((PRGO)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perrigo’s latest earnings call balanced clear operational progress against meaningful near-term headwinds. Management highlighted stronger margins, cash generation, and share gains, yet the tone was tempered by a large goodwill impairment, steep Infant Formula declines, and cyclical softness in U.S. OTC demand, framing 2026 as a transition year before a hoped-for recovery in 2027.
Core Earnings Growth Despite a Tough Backdrop
Perrigo reported that full-year All-In operating income rose 2% while All-In EPS climbed 7% to $2.75, showing resilience despite market pressures. On a CORE basis, operating income increased 7% and CORE EPS jumped 14%, with management positioning the 2025 CORE EPS of $2.52 as the baseline for future performance tracking.
Project Energize Drives Margin and Profit Gains
Operational initiatives under Project Energize and a broad supply-chain reinvention delivered about $320 million in benefits during 2025. These savings fed directly into operating income and EPS growth, underscoring that internal efficiency actions are cushioning the impact of weaker demand in several key categories.
Market Share Gains and New Distribution Wins
The company reported accelerating market share gains across key categories and geographies, suggesting its brands and private-label offerings are resonating with consumers and retailers. Perrigo also secured more than $100 million in new distribution and competitive takeaways, helped by stronger in-store execution and customer partnerships.
Tripled Innovation Pipeline Skews to Late 2026
Management said the innovation pipeline has tripled in value versus last year, reflecting a much richer slate of product launches and geographic expansions. Importantly, more than 60% of that innovation and opportunistic expansion is expected to land in the second half of 2026, making timing a key factor in the company’s recovery narrative.
Core 2026 Targets Signal a Transition Year
For CORE Perrigo in 2026, management guided to organic net sales growth ranging from a 3.5% decline to a modest 0.5% increase, highlighting the uncertain demand backdrop. CORE EPS is expected between $2.25 and $2.55 with gross margin of 39–40% and operating margin of 15–16%, implying flattish to slightly down earnings versus the 2025 CORE baseline.
New Cost Program and Workforce Reduction
To offset headwinds, Perrigo launched a two-year operational enhancement program targeting $80–$100 million in annualized pretax savings, with roughly 80% anticipated in 2026. Achieving these gains will require $80–$90 million in one-time costs and a roughly 7% global workforce reduction, introducing near-term execution and organizational risks.
Infant Formula Supply Stabilizes as Demand Softens
The company reported that Infant Formula service levels have recovered to above 90%, suggesting prior supply issues have been addressed. However, demand recovery has lagged and competition has intensified, creating a mismatch between operational readiness and actual consumption trends.
Balance Sheet, Leverage, and Margin Progress
Perrigo ended 2025 with $532 million in cash and generated $239 million in operating cash flow for the year, including $175 million in Q4. Net leverage improved from around 5.5 times to 4.0 times, and operating income margin has expanded roughly 230 basis points over the last two and a half years, marking tangible financial de-risking.
Regulatory and Quality Track Record Remains Solid
Management highlighted strong regulatory and quality performance, noting more than 30 inspections in 2025 with no critical or major observations. The absence of recalls underscores a robust quality assurance framework, which is particularly important in categories like Infant Formula and OTC medicines.
Infant Formula Revenues Under Strategic Review
Despite better service levels, Infant Formula net sales fell about 25% in the quarter and roughly 10% for the full year, sharply pressuring profitability. In Q4 alone, All-In operating income declined $29 million, including a negative $21 million impact from Infant Formula, prompting management to put the business under strategic review as a continuing drag.
Heavy Goodwill Impairment Weighs on GAAP Results
Perrigo’s 2025 GAAP results were hit by a $1.3 billion noncash goodwill impairment charge, reflecting reassessed expectations for certain businesses. Management also warned that additional noncash goodwill impairments of up to $350 million could be recorded in the first quarter of 2026 as goodwill is redistributed to new reporting units.
Soft OTC Environment Adds to Near-Term Pressure
The U.S. OTC market has turned into a headwind, with category consumption down 5.1% over the last 13 weeks compared with a 4.3% decline in Q4 and a 1.2% decline for full-year 2025. Management expects negative consumption trends to persist into the first half of 2026, particularly due to a weak cough and cold season impacting volumes.
Q4 Core Sales, Profits, and EPS Under Strain
In the fourth quarter, CORE organic net sales declined 2% despite continued share gains, illustrating how category weakness can overwhelm individual brand strength. CORE operating income slipped $4 million, or 2%, which translated into CORE EPS of $0.76, down $0.02 year over year and signaling near-term earnings pressure.
Underabsorption to Hit 2026 EPS
Lower 2025 production volumes are expected to drive temporary plant underabsorption in 2026, creating a significant near-term earnings drag. Management estimated this dynamic will hit CORE Perrigo EPS by about $0.60 in 2026, underscoring that some margin pressure is cost-structure related rather than purely demand-driven.
All-In 2026 Outlook Reflects Broad Weakness
On an All-In basis, and assuming a Dermacosmetics divestiture in the second quarter, Perrigo expects 2026 net sales to decline 5.5% to 1.5%. All-In EPS is projected between $2.00 and $2.30, signaling material pressure relative to 2025 as Infant Formula and underabsorption weigh on the consolidated P&L.
Working Capital and Cash Flow Conversion Challenges
The company built up Infant Formula inventories in 2025 in anticipation of stronger demand and import trends, which did not fully materialize. This has inflated working capital and will likely constrain free cash flow conversion in 2026, even though management expects some relief as inventories are drawn down over the year.
Guidance and Outlook Point to a Back-Half Recovery
For 2026, Perrigo expects CORE EPS of $2.25–$2.55, with about 30–35% of earnings in the first half and 65–70% weighted to the second half as innovation and cost savings ramp. Cash-flow conversion is targeted in the mid-60% range and net leverage is expected to finish 2026 roughly in line with or slightly better than the current 4.0 times, even as management cautioned about potential additional noncash goodwill impairments.
Perrigo’s earnings call painted a picture of a company that has strengthened its operations and balance sheet but is navigating tough category dynamics and structural issues in Infant Formula. Investors are being asked to look through a difficult 2026, marked by impairments, cost cuts, and EPS headwinds, to a potential 2027 rebound driven by a larger innovation pipeline and significant cost savings already in motion.
